Published in Br J Pharmacol on May 01, 2012
Persistent immune activation in chronic HIV infection: do any interventions work? AIDS (2013) 1.24
Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat Med (2015) 0.91
Biophysical techniques for detection of cAMP and cGMP in living cells. Int J Mol Sci (2013) 0.88
Proinflammatory and immunoregulatory roles of eicosanoids in T cells. Front Immunol (2013) 0.87
Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. Br J Pharmacol (2013) 0.84
Multiple facets of cAMP signalling and physiological impact: cAMP compartmentalization in the lung. Pharmaceuticals (Basel) (2012) 0.82
Pituitary adenylate cyclase activating peptide deficient mice exhibit impaired thymic and extrathymic regulatory T cell proliferation during EAE. PLoS One (2013) 0.81
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res (2016) 0.79
Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units. Front Immunol (2016) 0.77
Combined use of pharmacophoric models together with drug metabolism and genotoxicity "in silico" studies in the hit finding process. J Comput Aided Mol Des (2013) 0.77
PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. Br J Pharmacol (2015) 0.77
Prostaglandin E2 Inhibition of IL-27 Production in Murine Dendritic Cells: A Novel Mechanism That Involves IRF1. J Immunol (2017) 0.75
The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection. BMC Infect Dis (2016) 0.75
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev (2006) 10.24
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Foxp3-dependent programme of regulatory T-cell differentiation. Nature (2007) 9.48
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Natural versus adaptive regulatory T cells. Nat Rev Immunol (2003) 8.74
ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol (2002) 8.41
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev (2001) 7.60
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Cyclic nucleotide-gated ion channels. Physiol Rev (2002) 5.71
T cell dynamics in HIV-1 infection. Annu Rev Immunol (2001) 5.29
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer (2001) 4.62
ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol (1994) 4.09
Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature (2000) 4.01
Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. J Cell Biol (1993) 3.96
Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood (2001) 3.66
Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol (2004) 3.58
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40
T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol (2006) 3.40
Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol (1998) 3.39
Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol (2001) 3.21
Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol (2010) 3.01
Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev (2007) 2.91
Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med (2007) 2.88
Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr (2002) 2.70
Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol (2007) 2.69
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol (2005) 2.48
The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today (1989) 2.41
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res (2005) 2.32
miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep (2008) 1.96
Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med (2001) 1.79
Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol (2001) 1.69
Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett (2005) 1.66
Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex. Science (1994) 1.59
Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk. J Biol Chem (2000) 1.48
Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J Biol Chem (2006) 1.48
Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother (2002) 1.47
Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells. Cell Signal (2010) 1.46
Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med (2006) 1.45
Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal (2002) 1.45
FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol (2006) 1.43
Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem (1992) 1.37
Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology (2000) 1.31
Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts. J Biol Chem (2001) 1.29
Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency--involvement of protein kinase A type I. J Immunol (2003) 1.25
Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother (2007) 1.24
TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol (2004) 1.23
Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. Clin Cancer Res (2005) 1.21
Inhibition of T cell activation by cyclic adenosine 5'-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. J Immunol (2007) 1.19
The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J Immunol (2006) 1.18
Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med (Berl) (2001) 1.08
Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J Immunol (2002) 1.08
Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J (1998) 1.07
Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol (2008) 1.06
An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol (2011) 1.05
Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J Immunol (1999) 1.05
Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther (2009) 1.04
Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase a signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex. Mol Cell Biol (2010) 1.01
Dual specificity A-kinase anchoring proteins (AKAPs) contain an additional binding region that enhances targeting of protein kinase A type I. J Biol Chem (2008) 0.99
Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity. J Biol Chem (1997) 0.97
Cyclic AMP-dependent protein kinase (cAK) in human B cells: co-localization of type I cAK (RI alpha 2 C2) with the antigen receptor during anti-immunoglobulin-induced B cell activation. Eur J Immunol (1996) 0.96
PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples. Curr HIV Res (2008) 0.94
Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase a inhibits T cell receptor signaling. J Biol Chem (2003) 0.92
The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer (2007) 0.91
High-resolution mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells. Blood (2010) 0.90
Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation. Expert Opin Biol Ther (2011) 0.89
Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. Crit Rev Oncog (2008) 0.89
Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS (2006) 0.88
Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB J (2005) 0.88
Multiple cAMP-induced signaling cascades regulate prolactin expression in T cells. Cell Mol Life Sci (2006) 0.86
Prostaglandin E₂ regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells. Biochem Pharmacol (2010) 0.85
Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART. AIDS (1999) 0.85
Molecular architecture of signal complexes regulating immune cell function. Handb Exp Pharmacol (2008) 0.85
The adaptor protein EBP50 is important for localization of the protein kinase A-Ezrin complex in T-cells and the immunomodulating effect of cAMP. Biochem J (2009) 0.84
Elevation of cyclic AMP in Jurkat T-cells provokes distinct transcriptional responses through the protein kinase A (PKA) and exchange protein activated by cyclic AMP (EPAC) pathways. Exp Cell Res (2005) 0.83
Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. Eur J Immunol (2009) 0.83
Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection. Clin Exp Immunol (2010) 0.83
Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines. Clin Med (2008) 0.80
Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced immunodeficiency. J Immunol (2011) 0.80
Regulation of T cells in airway disease by beta-agonist. Front Biosci (Schol Ed) (2010) 0.79
Cancer: do aspirin and other NSAIDs protect against colorectal cancer? Nat Rev Gastroenterol Hepatol (2011) 0.79
Predictive value of immunologic parameters and HIV RNA in relation to humoral pneumococcal polysaccharide vaccine responses in patients with HIV infection. Eur J Clin Microbiol Infect Dis (2002) 0.77
Prostaglandin E2 secretion by subsets of human peripheral blood monocytes. Immunopharmacology (1982) 0.76
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet (2005) 6.48
Molecular basis of AKAP specificity for PKA regulatory subunits. Mol Cell (2006) 2.33
Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem J (2003) 1.84
PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood (2010) 1.76
AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep (2007) 1.72
Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under the control of cAMP. AIDS (2004) 1.54
Specificity and spatial dynamics of protein kinase A signaling organized by A-kinase-anchoring proteins. J Mol Endocrinol (2010) 1.52
Diastolic dysfunction in alveolar hypoxia: a role for interleukin-18-mediated increase in protein phosphatase 2A. Cardiovasc Res (2008) 1.49
Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J Biol Chem (2006) 1.48
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol (2006) 1.47
Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells. Cell Signal (2010) 1.46
Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal (2002) 1.45
Creating order from chaos: cellular regulation by kinase anchoring. Annu Rev Pharmacol Toxicol (2012) 1.44
FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol (2006) 1.43
The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. J Biol Chem (2004) 1.37
Generation of highly suppressive adaptive CD8(+)CD25(+)FOXP3(+) regulatory T cells by continuous antigen stimulation. Eur J Immunol (2008) 1.28
Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency--involvement of protein kinase A type I. J Immunol (2003) 1.25
Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother (2007) 1.24
TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol (2004) 1.23
Haematopoietic protein tyrosine phosphatase (HePTP) phosphorylation by cAMP-dependent protein kinase in T-cells: dynamics and subcellular location. Biochem J (2004) 1.20
Inhibition of T cell activation by cyclic adenosine 5'-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. J Immunol (2007) 1.19
The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J Immunol (2006) 1.18
LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int Immunol (2007) 1.09
Mechanisms of FOXC2- and FOXD1-mediated regulation of the RI alpha subunit of cAMP-dependent protein kinase include release of transcriptional repression and activation by protein kinase B alpha and cAMP. J Biol Chem (2002) 1.08
Optic atrophy 1 is an A-kinase anchoring protein on lipid droplets that mediates adrenergic control of lipolysis. EMBO J (2011) 1.06
Reciprocal regulation of SH3 and SH2 domain binding via tyrosine phosphorylation of a common site in CD3epsilon. J Immunol (2007) 1.05
An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol (2011) 1.05
CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets. J Immunol (2003) 1.03
Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase a signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex. Mol Cell Biol (2010) 1.01
CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-activated human regulatory T cells. Blood (2011) 1.00
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother (2015) 0.99
Dual specificity A-kinase anchoring proteins (AKAPs) contain an additional binding region that enhances targeting of protein kinase A type I. J Biol Chem (2008) 0.99
Distinct but overlapping domains of AKAP95 are implicated in chromosome condensation and condensin targeting. EMBO Rep (2002) 0.99
Characterization of A-kinase-anchoring disruptors using a solution-based assay. Biochem J (2006) 0.98
Insulin and TNF alpha induce expression of the forkhead transcription factor gene Foxc2 in 3T3-L1 adipocytes via PI3K and ERK 1/2-dependent pathways. Mol Endocrinol (2002) 0.97
Protein kinase A-anchoring protein AKAP95 interacts with MCM2, a regulator of DNA replication. J Biol Chem (2003) 0.97
Merlin links to the cAMP neuronal signaling pathway by anchoring the RIbeta subunit of protein kinase A. J Biol Chem (2003) 0.95
Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase a inhibits T cell receptor signaling. J Biol Chem (2003) 0.92
Regulation of FynT function by dual domain docking on PAG/Cbp. J Biol Chem (2007) 0.91
Protein kinase A intersects SRC signaling in membrane microdomains. J Biol Chem (2003) 0.91
The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3',5'-monophosphate pathway in various cell types. Endocrinology (2004) 0.91
Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells. Arterioscler Thromb Vasc Biol (2012) 0.91
High-resolution mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells. Blood (2010) 0.90
Activation of C-terminal Src kinase (Csk) by phosphorylation at serine-364 depends on the Csk-Src homology 3 domain. Biochem J (2003) 0.90
Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. Crit Rev Oncog (2008) 0.89
A novel human CD4+ T-cell inducer subset with potent immunostimulatory properties. Eur J Immunol (2010) 0.89
Reduced Cbl phosphorylation and degradation of the zeta-chain of the T-cell receptor/CD3 complex in T cells with low Lck levels. Eur J Immunol (2008) 0.88
Reduced PDE4 expression and activity contributes to enhanced catecholamine-induced cAMP accumulation in adipocytes from FOXC2 transgenic mice. FEBS Lett (2006) 0.88
Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS (2006) 0.88
Spatiotemporal control of cyclic AMP immunomodulation through the PKA-Csk inhibitory pathway is achieved by anchoring to an Ezrin-EBP50-PAG scaffold in effector T cells. FEBS Lett (2010) 0.87
Proinflammatory and immunoregulatory roles of eicosanoids in T cells. Front Immunol (2013) 0.87
Splicing factor arginine/serine-rich 17A (SFRS17A) is an A-kinase anchoring protein that targets protein kinase A to splicing factor compartments. J Biol Chem (2009) 0.86
Differentiation of naive CD4+ T cells into CD4+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation. J Leukoc Biol (2008) 0.86
Mutually exclusive binding of PP1 and RNA to AKAP149 affects the mitochondrial network. Hum Mol Genet (2008) 0.86
The heterotrimeric G-protein alpha-subunit Galphaq regulates TCR-mediated immune responses through an Lck-dependent pathway. Eur J Immunol (2008) 0.85
Interplay between the heterotrimeric G-protein subunits Galphaq and Galphai2 sets the threshold for chemotaxis and TCR activation. BMC Immunol (2009) 0.85
Novel mechanism of signaling by CD28. Immunol Lett (2010) 0.85
The potential use of AKAP18delta as a drug target in heart failure patients. Expert Opin Biol Ther (2008) 0.85
Protein kinase A antagonist inhibits β-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/+) mice. Mol Cancer (2011) 0.85
Interactions between the Fyn SH3-domain and adaptor protein Cbp/PAG derived ligands, effects on kinase activity and affinity. FEBS J (2008) 0.84
T-cell co-stimulation through the CD2 and CD28 co-receptors induces distinct signalling responses. Biochem J (2014) 0.84
The adaptor protein EBP50 is important for localization of the protein kinase A-Ezrin complex in T-cells and the immunomodulating effect of cAMP. Biochem J (2009) 0.84
Kinetics and activation requirements of contact-dependent immune suppression by human regulatory T cells. J Immunol (2012) 0.84
Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. Eur J Immunol (2009) 0.83
CD147 in regulatory T cells. Cell Immunol (2013) 0.83
CD8+ regulatory T cells-A distinct T-cell lineage or a transient T-cell phenotype? Hum Immunol (2008) 0.82
A human whole blood model of LPS-mediated suppression of T cell activation. Med Sci Monit (2003) 0.82
Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunol Immunother (2014) 0.81
Analysing phosphorylation-based signalling networks by phospho flow cytometry. Cell Signal (2010) 0.81
Quantitative proteome analysis of detergent-resistant membranes identifies the differential regulation of protein kinase C isoforms in apoptotic T cells. Proteomics (2010) 0.81
Role of cAMP phosphodiesterase 4 in regulation of T-cell function. Crit Rev Immunol (2006) 0.81
Modulation of proximal signaling in normal and transformed B cells by transmembrane adapter Cbp/PAG. Exp Cell Res (2012) 0.81
Effect of activated platelets on expression of cytokines in peripheral blood mononuclear cells - potential role of prostaglandin E2. Thromb Haemost (2004) 0.80
Design of proteolytically stable RI-anchoring disruptor peptidomimetics for in vivo studies of anchored type I protein kinase A-mediated signalling. Biochem J (2009) 0.80
Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced immunodeficiency. J Immunol (2011) 0.80
Endosome-to-Golgi transport is regulated by protein kinase A type II alpha. J Biol Chem (2002) 0.79
Aggressive treatment of patients with metastatic colorectal cancer increases survival: a scandinavian single-center experience. HPB Surg (2013) 0.79
A kinase anchoring protein (AKAP) interaction and dimerization of the RIalpha and RIbeta regulatory subunits of protein kinase a in vivo by the yeast two hybrid system. J Mol Biol (2003) 0.78
A winged helix forkhead (FOXD2) tunes sensitivity to cAMP in T lymphocytes through regulation of cAMP-dependent protein kinase RIalpha. J Biol Chem (2003) 0.78
Hypophosphorylated TCR/CD3zeta signals through a Grb2-SOS1-Ras pathway in Lck knockdown cells. Eur J Immunol (2007) 0.78
Phosphodiesterases as targets for modulating T-cell responses. Handb Exp Pharmacol (2011) 0.78
Cell signalling analyses in the functional genomics era. N Biotechnol (2013) 0.78
Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. Cancer Immunol Immunother (2011) 0.77
USF2 inhibits C/EBP-mediated transcriptional regulation of the RIIbeta subunit of cAMP-dependent protein kinase. BMC Mol Biol (2002) 0.77
Electrical muscle activity pattern and transcriptional and posttranscriptional mechanisms regulate PKA subunit expression in rat skeletal muscle. Mol Cell Neurosci (2002) 0.77
Stereoselective preparation of (RP)-8-hetaryladenosine-3',5'-cyclic phosphorothioic acids. Org Biomol Chem (2007) 0.77
Quantitative profiling of tyrosine phosphorylation revealed changes in the activity of the T cell receptor signaling pathway upon cisplatin-induced apoptosis. J Proteomics (2013) 0.76
A phenotypic screening approach to identify anticancer compounds derived from marine fungi. Assay Drug Dev Technol (2014) 0.76
The RIAD peptidomimetic inhibits HIV-1 replication in humanized NSG mice. Eur J Clin Invest (2013) 0.76
Inhibition of protein kinase A improves effector function of monocytes from HIV-infected patients. AIDS Res Hum Retroviruses (2008) 0.76
EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry. J Neurooncol (2013) 0.75
Stereoselective synthesis of (RP)-8-substituted-N⁶-acylated and N⁶-alkylated adenosine-3',5'-cyclic phosphorothioic acids as cAMP antagonists. Eur J Med Chem (2011) 0.75
A fast and sensitive method for isolation of detergent-resistant membranes from T cells. J Immunol Methods (2005) 0.75
Plasma IP-10 Is Increased in Immunological NonResponders and Associated With Activated Regulatory T Cells and Persisting Low CD4 Counts. J Acquir Immune Defic Syndr (2016) 0.75